Press Room

Press Clipping / Sep 26, 2020

Hovione warp-speeds Ligand’s excipient

C&EN, September 26, 2020

Hovione has signed an agreement to significantly ramp up output of Ligand Pharmaceuticals’ Captisol, a chemically modified cyclodextrin that improves drugs’ solubility and stability. Gilead Sciences uses the excipient to formulate the COVID-19 treatment remdesivir. “Hovione will soon be producing per month the quantity it usually produces in one year,” Jean-Luc Herbeaux, its chief operating officer, says in a press release. Hovione is the sole producer of Captisol under a longstanding partnership with Ligand.

Read the article on C&EN

Also in the Press Room